Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Laboratory for Molecular Medicine, |
RCV000220422 | SCV000272441 | uncertain significance | not specified | 2016-01-12 | criteria provided, single submitter | clinical testing | The p.Met147Ile variant in SLC26A4 has been reported in 1 individual with unilat eral hearing loss and enlargement of the vestibular aqueduct (EVA) who did not h ave a second SLC26A4 variant (Jonard 2010). This variant has also been identifie d in 0.5% (35/6614) of Finnish chromosomes by the Exome Aggregation Consortium ( ExAC, http://exac.broadinstitute.org; dbSNP rs201905280). Although this variant has been seen in the general population, its frequency is not high enough to rul e out a pathogenic role. Computational prediction tools and conservation analyse s suggest that the p.Met147Ile variant may impact the protein, though this infor mation is not predictive enough to determine pathogenicity. Two additional varia nts at this position (p.Met147Val and p.Met147Thr) have also previously been rep orted in individuals with hearing loss and EVA. The p.Met147Val variant has been reported in at least 5 individuals with hearing loss and EVA all of whom were c ompound heterozygous for a second pathogenic SLC26A4 variant, and functional stu dies suggest that protein function may be altered (Park 2005, Albert 2006, Yoon 2008, Ishihara 2010, Huang 2011). The p.Met147Thr variant has been observed in a t least 3 homozygous individuals with hearing loss and segregated with hearing l oss in 1 family (Albert 2006, Rebeh 2010). In summary, the clinical significance of the p.Met147Ile variant is uncertain. |
| Counsyl | RCV000669107 | SCV000793816 | uncertain significance | Pendred syndrome | 2017-11-14 | criteria provided, single submitter | clinical testing |